Colorado BioScience Association Appoints New Board Members
By: Colorado BioScience Association Date: 04/26/2021
Colorado BioScience Association (CBSA) today announced the appointment of seven new members to its board of directors, Jim Kasic, CEO of EndoShape and Chairman of Boulder IQ; Anil Mathai, Vice President, Quality and Regulatory Compliance of STAQ Pharma; Rita (“Ruta”) Sanzgiri, Shareholder, Sheridan Ross; Jodi Scott, Partner, Hogan Lovells; Roy Smythe, CEO of SomaLogic; Corey Stone, Executive Director of Essent Biologics; and Tanya Warnecke, Chief Technology Officer of Artisan Bio.
Selected for their leadership at companies of all stages of commercialization and expertise in issues that impact Colorado’s life sciences community, the new members will support the health and growth of CBSA and serve a three-year team. The 28-person CBSA Board of Directors is comprised of representatives from the state’s biotechnology, medical device, diagnostic, pharmaceutical, ag bio, digital health, healthcare, and research organizations.
Jim Kasic, M.S. M.B.A., CEO of EndoShape and Chairman of Boulder IQ is a serial entrepreneur with more than 30 years of experience in the Class I, II, and III medical device industry, ranging from multi-national corporations to start-ups. He holds more than 40 U.S. and international patents.
Anil Mathai, M.B.A., Vice President, Quality and Regulatory Compliance of STAQ Pharma has over 22 years in FDA-related industries like pharmaceuticals and provides leadership on strategy, vision, and development of quality systems to ensure adherence with customer and regulatory expectations.
Rita (“Ruta”) Sanzgiri, Ph.D., J.D., Shareholder, Sheridan Ross is a registered patent attorney who helps her clients design, build and maintain global patent portfolios to protect their innovations in the general areas of life-sciences, pharmaceuticals, and biotechnology.
Jodi Scott, J.D., Partner, Hogan Lovells is a Food and Drug Attorney who specializes in counseling her medical device clients on how to satisfy the US FDA requirements for obtaining market authorization and satisfying the postmarket regulatory obligations, including imports/export, advertising and promotion, and QSR compliance.
Roy Smythe, M.D., CEO, SomaLogic is an internationally recognized surgeon, biomedical scientist, academician, health system administrator and healthcare business entrepreneur. Before joining SomaLogic, he served as Global Chief Medical Officer for Strategy and Partnerships at Royal Philips.
Corey Stone, M.B.A., Executive Director, Essent Biologics oversees start-up activities by operationalizing the organization’s strategic vision and mission. He also leads the development and execution of the company’s strategy. Before joining Essent Biologics, he served as the Senior Vice President of Innovation for AlloSource.
Tanya Warnecke, President and Chief Technology Officer, Artisan BIO is an executive-level professional with a background in cell engineering startups and life sciences tools. Prior to Artisan, she was the co-founder, CTO, and VP of Applications at Inscripta and is the inventor on 20+ patent filings.
Jennifer Jones Paton, CBSA President and CEO, said:
“CBSA warmly welcomes the newest members of our board of directors, who are respected leaders at their own companies and organizations. Jim, Anil, Corey, Jodi, Rita, Roy, and Tanya bring deep experience and fresh perspectives to Colorado BioScience Association. They are thought leaders who are committed to the growth, health, and vitality of life sciences in the state.”
Bob Reddy, Vice President of Global Marketing, Medical Education and Training, Medtronic Enabling Technologies, CBSA Board of Directors Chair, said:
“Our seven new board members represent the best of Colorado’s life sciences community. They replace a group of dynamic leaders who generously shared their expertise and time with CBSA. We thank our outgoing board members Larry Blankenship, Jim Cloar, Gary Connell, Sally Dyer, Charlie Kang, Scott Larson, Fintan Steele, Steve Warnecke and Shelley Zelin for their service to Colorado BioScience Association and their leadership in Colorado’s life sciences community.”
Kiki Traylor, M.D., Director of State Government Affairs, Amgen, CBSA Board of Directors Vice Chair, said:
“As Colorado emerges from the pandemic, CBSA stands ready to support our members’ critical work of health innovation. We look forward to new ideas, opportunities for partnership and growth strategies with the addition of our new board members.”
Additionally, six new members were reappointed to the CBSA board for a three-year term.
Gino DiSciullo, Ph.D. Partner, Capital Midwest Fund
Brent Fassett, J.D., Partner, Cooley, LLP
Mark Lupa, Ph.D., Managing Partner, High Country Venture and Senior Advisor, Venture Partners at CU Boulder
Ethan Mann, Ph.D., M.B.A., CEO, Validus Cellular Therapeutics
Kiki Traylor, M.D., Director, State Government Affairs, Amgen
Dan Wittenberg, J.D., Partner, Snell & Wilmer
Board members work in partnership with CBSA staff to support the growth of Colorado’s more than 720 life sciences companies. Names and photos of the full board of directors are available on the CBSA website.
About Colorado BioScience Association
Colorado BioScience Association (CBSA) creates co-opportunity for the Colorado life sciences community. CBSA champions a collaborative life sciences ecosystem and advocates for a supportive business climate. From concept to commercialization, member companies and organizations drive global health innovations, products and services that improve and save lives. The association leads Capital and Growth, Education and Networking, Policy and Advocacy, and Workforce Cultivation to make its members stronger, together. Learn more: cobioscience.com
# # #
Primavera Group for Colorado BioScience Association